PubMed:17255138 JSONTXT

{"project":"LitCoin-entities","denotations":[{"id":"3881","span":{"begin":22,"end":38},"obj":"ChemicalEntity"},{"id":"3882","span":{"begin":56,"end":62},"obj":"ChemicalEntity"},{"id":"3883","span":{"begin":188,"end":215},"obj":"DiseaseOrPhenotypicFeature"},{"id":"3884","span":{"begin":217,"end":220},"obj":"DiseaseOrPhenotypicFeature"},{"id":"3885","span":{"begin":227,"end":243},"obj":"ChemicalEntity"},{"id":"3886","span":{"begin":324,"end":361},"obj":"ChemicalEntity"},{"id":"3887","span":{"begin":363,"end":369},"obj":"ChemicalEntity"},{"id":"3888","span":{"begin":425,"end":428},"obj":"DiseaseOrPhenotypicFeature"},{"id":"3889","span":{"begin":433,"end":444},"obj":"DiseaseOrPhenotypicFeature"},{"id":"3890","span":{"begin":474,"end":490},"obj":"ChemicalEntity"},{"id":"3891","span":{"begin":495,"end":501},"obj":"ChemicalEntity"},{"id":"3892","span":{"begin":506,"end":519},"obj":"ChemicalEntity"},{"id":"3893","span":{"begin":662,"end":667},"obj":"ChemicalEntity"},{"id":"3894","span":{"begin":671,"end":684},"obj":"ChemicalEntity"},{"id":"3895","span":{"begin":838,"end":845},"obj":"ChemicalEntity"},{"id":"3896","span":{"begin":862,"end":875},"obj":"ChemicalEntity"},{"id":"3897","span":{"begin":887,"end":896},"obj":"ChemicalEntity"},{"id":"3898","span":{"begin":907,"end":916},"obj":"ChemicalEntity"},{"id":"3899","span":{"begin":935,"end":941},"obj":"ChemicalEntity"},{"id":"3900","span":{"begin":958,"end":965},"obj":"ChemicalEntity"},{"id":"3901","span":{"begin":988,"end":997},"obj":"ChemicalEntity"},{"id":"3902","span":{"begin":1009,"end":1018},"obj":"ChemicalEntity"},{"id":"3903","span":{"begin":1032,"end":1038},"obj":"ChemicalEntity"},{"id":"3904","span":{"begin":1053,"end":1066},"obj":"ChemicalEntity"},{"id":"3905","span":{"begin":1087,"end":1094},"obj":"ChemicalEntity"},{"id":"3906","span":{"begin":1172,"end":1175},"obj":"DiseaseOrPhenotypicFeature"},{"id":"3907","span":{"begin":1186,"end":1199},"obj":"ChemicalEntity"},{"id":"3908","span":{"begin":1209,"end":1216},"obj":"ChemicalEntity"},{"id":"3909","span":{"begin":1230,"end":1239},"obj":"ChemicalEntity"},{"id":"3910","span":{"begin":1259,"end":1268},"obj":"ChemicalEntity"},{"id":"3911","span":{"begin":1288,"end":1296},"obj":"ChemicalEntity"},{"id":"3912","span":{"begin":1316,"end":1326},"obj":"ChemicalEntity"},{"id":"3913","span":{"begin":1349,"end":1358},"obj":"ChemicalEntity"},{"id":"3914","span":{"begin":1393,"end":1400},"obj":"ChemicalEntity"},{"id":"3915","span":{"begin":1413,"end":1422},"obj":"ChemicalEntity"},{"id":"3916","span":{"begin":1442,"end":1451},"obj":"ChemicalEntity"},{"id":"3917","span":{"begin":1471,"end":1480},"obj":"ChemicalEntity"},{"id":"3918","span":{"begin":1500,"end":1510},"obj":"ChemicalEntity"},{"id":"3919","span":{"begin":1530,"end":1538},"obj":"ChemicalEntity"},{"id":"3920","span":{"begin":1561,"end":1574},"obj":"ChemicalEntity"},{"id":"3921","span":{"begin":1625,"end":1632},"obj":"ChemicalEntity"},{"id":"3922","span":{"begin":1634,"end":1642},"obj":"ChemicalEntity"},{"id":"3923","span":{"begin":1680,"end":1683},"obj":"DiseaseOrPhenotypicFeature"},{"id":"3924","span":{"begin":1684,"end":1695},"obj":"DiseaseOrPhenotypicFeature"},{"id":"3925","span":{"begin":1701,"end":1704},"obj":"DiseaseOrPhenotypicFeature"},{"id":"3926","span":{"begin":1705,"end":1716},"obj":"DiseaseOrPhenotypicFeature"},{"id":"3927","span":{"begin":1720,"end":1729},"obj":"ChemicalEntity"},{"id":"3928","span":{"begin":1753,"end":1766},"obj":"ChemicalEntity"},{"id":"3929","span":{"begin":1805,"end":1814},"obj":"ChemicalEntity"},{"id":"3930","span":{"begin":1822,"end":1828},"obj":"ChemicalEntity"},{"id":"3931","span":{"begin":1845,"end":1852},"obj":"ChemicalEntity"},{"id":"3932","span":{"begin":1859,"end":1868},"obj":"ChemicalEntity"},{"id":"3933","span":{"begin":1873,"end":1881},"obj":"ChemicalEntity"}],"attributes":[{"id":"A35","pred":"db_id","subj":"3915","obj":"MESH:C116926"},{"id":"A27","pred":"db_id","subj":"3907","obj":"MESH:D000082"},{"id":"A30","pred":"db_id","subj":"3910","obj":"MESH:C105934"},{"id":"A46","pred":"db_id","subj":"3926","obj":"MESH:D005767"},{"id":"A37","pred":"db_id","subj":"3917","obj":"MESH:D007052"},{"id":"A9","pred":"db_id","subj":"3889","obj":"MESH:D006471"},{"id":"A24","pred":"db_id","subj":"3904","obj":"MESH:D000082"},{"id":"A53","pred":"db_id","subj":"3933","obj":"MESH:D009288"},{"id":"A15","pred":"db_id","subj":"3895","obj":"MESH:D001241"},{"id":"A22","pred":"db_id","subj":"3902","obj":"MESH:C105934"},{"id":"A33","pred":"db_id","subj":"3913","obj":"MESH:D007052"},{"id":"A32","pred":"db_id","subj":"3912","obj":"MESH:D004008"},{"id":"A52","pred":"db_id","subj":"3932","obj":"MESH:C105934"},{"id":"A7","pred":"db_id","subj":"3887","obj":"MESH:D000894"},{"id":"A19","pred":"db_id","subj":"3899","obj":"MESH:D000894"},{"id":"A17","pred":"db_id","subj":"3897","obj":"MESH:C116926"},{"id":"A20","pred":"db_id","subj":"3900","obj":"MESH:D001241"},{"id":"A23","pred":"db_id","subj":"3903","obj":"MESH:D000894"},{"id":"A48","pred":"db_id","subj":"3928","obj":"MESH:D000082"},{"id":"A1","pred":"db_id","subj":"3881","obj":"MESH:D052246"},{"id":"A18","pred":"db_id","subj":"3898","obj":"MESH:C105934"},{"id":"A6","pred":"db_id","subj":"3886","obj":"MESH:D000894"},{"id":"A29","pred":"db_id","subj":"3909","obj":"MESH:C116926"},{"id":"A25","pred":"db_id","subj":"3905","obj":"MESH:D001241"},{"id":"A39","pred":"db_id","subj":"3919","obj":"MESH:D009288"},{"id":"A16","pred":"db_id","subj":"3896","obj":"MESH:D000082"},{"id":"A21","pred":"db_id","subj":"3901","obj":"MESH:C116926"},{"id":"A36","pred":"db_id","subj":"3916","obj":"MESH:C105934"},{"id":"A4","pred":"db_id","subj":"3884","obj":"MESH:D009203"},{"id":"A28","pred":"db_id","subj":"3908","obj":"MESH:D001241"},{"id":"A41","pred":"db_id","subj":"3921","obj":"MESH:D001241"},{"id":"A2","pred":"db_id","subj":"3882","obj":"MESH:D000894"},{"id":"A31","pred":"db_id","subj":"3911","obj":"MESH:D009288"},{"id":"A49","pred":"db_id","subj":"3929","obj":"MESH:C116926"},{"id":"A13","pred":"db_id","subj":"3893","obj":"MESH:D000894"},{"id":"A42","pred":"db_id","subj":"3922","obj":"MESH:D009288"},{"id":"A51","pred":"db_id","subj":"3931","obj":"MESH:D001241"},{"id":"A14","pred":"db_id","subj":"3894","obj":"MESH:D000082"},{"id":"A26","pred":"db_id","subj":"3906","obj":"MESH:D009203"},{"id":"A38","pred":"db_id","subj":"3918","obj":"MESH:D004008"},{"id":"A40","pred":"db_id","subj":"3920","obj":"MESH:D000082"},{"id":"A3","pred":"db_id","subj":"3883","obj":"MESH:D009203"},{"id":"A47","pred":"db_id","subj":"3927","obj":"MESH:C105934"},{"id":"A12","pred":"db_id","subj":"3892","obj":"MESH:D000082"},{"id":"A50","pred":"db_id","subj":"3930","obj":"MESH:D000894"},{"id":"A5","pred":"db_id","subj":"3885","obj":"MESH:D052246"},{"id":"A10","pred":"db_id","subj":"3890","obj":"MESH:D052246"},{"id":"A11","pred":"db_id","subj":"3891","obj":"MESH:D000894"},{"id":"A8","pred":"db_id","subj":"3888","obj":"MESH:D009203"},{"id":"A45","pred":"db_id","subj":"3925","obj":"MESH:D009203"},{"id":"A34","pred":"db_id","subj":"3914","obj":"MESH:D001241"},{"id":"A43","pred":"db_id","subj":"3923","obj":"MESH:D009203"},{"id":"A44","pred":"db_id","subj":"3924","obj":"MESH:D006471"}],"namespaces":[{"prefix":"_base","uri":"https://w3id.org/biolink/vocab/"},{"prefix":"MESH","uri":"http://id.nlm.nih.gov/mesh/"},{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id="},{"prefix":"NCBIGene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"OMIM","uri":"https://www.omim.org/entry/"},{"prefix":"DBSNP","uri":"https://www.ncbi.nlm.nih.gov/snp/"}],"text":"Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.\nOBJECTIVES: The risk of acute myocardial infarction (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-selective (NS) non-steroidal anti-inflammatory drugs (NSAIDs). We aimed to compare the risks of hospitalization for AMI and GI bleeding among elderly patients using COX-2 inhibitors, NS-NSAIDs and acetaminophen.\nMETHODS: We conducted a retrospective cohort study using administrative data of patients \u003e or =65 years of age who filled a prescription for NSAID or acetaminophen during 1999-2002. Outcomes were compared using Cox regression models with time-dependent exposures.\nRESULTS: Person-years of exposure among non-users of aspirin were: 75,761 to acetaminophen, 42,671 to rofecoxib 65,860 to celecoxib, and 37,495 to NS-NSAIDs. Among users of aspirin, they were: 14,671 to rofecoxib, 22,875 to celecoxib, 9,832 to NS-NSAIDs and 38,048 to acetaminophen. Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51). Among users of aspirin, they were: rofecoxib 1.73 (1.52, 1.98), celecoxib 1.34 (1.19, 1.52), ibuprofen 1.51 (0.95, 2.41), diclofenac 1.69 (1.35, 2.10), naproxen 1.35 (0.97, 1.88) and acetaminophen 1.29 (1.17, 1.42).\nCONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI/GI bleeding. The AMI/GI toxicity of celecoxib was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-NSAIDs. Among users of aspirin, both celecoxib and naproxen seemed to be the least toxic."}

{"project":"LitCoin-sentences","denotations":[{"id":"T1","span":{"begin":0,"end":133},"obj":"Sentence"},{"id":"T2","span":{"begin":134,"end":163},"obj":"Sentence"},{"id":"T3","span":{"begin":164,"end":175},"obj":"Sentence"},{"id":"T4","span":{"begin":176,"end":371},"obj":"Sentence"},{"id":"T5","span":{"begin":372,"end":520},"obj":"Sentence"},{"id":"T6","span":{"begin":521,"end":529},"obj":"Sentence"},{"id":"T7","span":{"begin":530,"end":702},"obj":"Sentence"},{"id":"T8","span":{"begin":703,"end":784},"obj":"Sentence"},{"id":"T9","span":{"begin":785,"end":793},"obj":"Sentence"},{"id":"T10","span":{"begin":794,"end":851},"obj":"Sentence"},{"id":"T11","span":{"begin":852,"end":942},"obj":"Sentence"},{"id":"T12","span":{"begin":943,"end":977},"obj":"Sentence"},{"id":"T13","span":{"begin":978,"end":1067},"obj":"Sentence"},{"id":"T14","span":{"begin":1068,"end":1377},"obj":"Sentence"},{"id":"T15","span":{"begin":1378,"end":1593},"obj":"Sentence"},{"id":"T16","span":{"begin":1594,"end":1605},"obj":"Sentence"},{"id":"T17","span":{"begin":1606,"end":1696},"obj":"Sentence"},{"id":"T18","span":{"begin":1697,"end":1829},"obj":"Sentence"},{"id":"T19","span":{"begin":1830,"end":1911},"obj":"Sentence"}],"text":"Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.\nOBJECTIVES: The risk of acute myocardial infarction (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-selective (NS) non-steroidal anti-inflammatory drugs (NSAIDs). We aimed to compare the risks of hospitalization for AMI and GI bleeding among elderly patients using COX-2 inhibitors, NS-NSAIDs and acetaminophen.\nMETHODS: We conducted a retrospective cohort study using administrative data of patients \u003e or =65 years of age who filled a prescription for NSAID or acetaminophen during 1999-2002. Outcomes were compared using Cox regression models with time-dependent exposures.\nRESULTS: Person-years of exposure among non-users of aspirin were: 75,761 to acetaminophen, 42,671 to rofecoxib 65,860 to celecoxib, and 37,495 to NS-NSAIDs. Among users of aspirin, they were: 14,671 to rofecoxib, 22,875 to celecoxib, 9,832 to NS-NSAIDs and 38,048 to acetaminophen. Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51). Among users of aspirin, they were: rofecoxib 1.73 (1.52, 1.98), celecoxib 1.34 (1.19, 1.52), ibuprofen 1.51 (0.95, 2.41), diclofenac 1.69 (1.35, 2.10), naproxen 1.35 (0.97, 1.88) and acetaminophen 1.29 (1.17, 1.42).\nCONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI/GI bleeding. The AMI/GI toxicity of celecoxib was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-NSAIDs. Among users of aspirin, both celecoxib and naproxen seemed to be the least toxic."}

{"project":"LitCoin_Mondo","denotations":[{"id":"T1","span":{"begin":188,"end":215},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":194,"end":215},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"0004781"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"0005068"}],"text":"Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.\nOBJECTIVES: The risk of acute myocardial infarction (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-selective (NS) non-steroidal anti-inflammatory drugs (NSAIDs). We aimed to compare the risks of hospitalization for AMI and GI bleeding among elderly patients using COX-2 inhibitors, NS-NSAIDs and acetaminophen.\nMETHODS: We conducted a retrospective cohort study using administrative data of patients \u003e or =65 years of age who filled a prescription for NSAID or acetaminophen during 1999-2002. Outcomes were compared using Cox regression models with time-dependent exposures.\nRESULTS: Person-years of exposure among non-users of aspirin were: 75,761 to acetaminophen, 42,671 to rofecoxib 65,860 to celecoxib, and 37,495 to NS-NSAIDs. Among users of aspirin, they were: 14,671 to rofecoxib, 22,875 to celecoxib, 9,832 to NS-NSAIDs and 38,048 to acetaminophen. Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51). Among users of aspirin, they were: rofecoxib 1.73 (1.52, 1.98), celecoxib 1.34 (1.19, 1.52), ibuprofen 1.51 (0.95, 2.41), diclofenac 1.69 (1.35, 2.10), naproxen 1.35 (0.97, 1.88) and acetaminophen 1.29 (1.17, 1.42).\nCONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI/GI bleeding. The AMI/GI toxicity of celecoxib was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-NSAIDs. Among users of aspirin, both celecoxib and naproxen seemed to be the least toxic."}

{"project":"LitCoin-GeneOrGeneProduct-v0","denotations":[{"id":"T1","span":{"begin":22,"end":27},"obj":"GeneOrGeneProduct"},{"id":"T2","span":{"begin":28,"end":38},"obj":"GeneOrGeneProduct"},{"id":"T3","span":{"begin":217,"end":220},"obj":"GeneOrGeneProduct"},{"id":"T4","span":{"begin":227,"end":232},"obj":"GeneOrGeneProduct"},{"id":"T5","span":{"begin":233,"end":243},"obj":"GeneOrGeneProduct"},{"id":"T6","span":{"begin":279,"end":281},"obj":"GeneOrGeneProduct"},{"id":"T7","span":{"begin":425,"end":428},"obj":"GeneOrGeneProduct"},{"id":"T8","span":{"begin":433,"end":435},"obj":"GeneOrGeneProduct"},{"id":"T9","span":{"begin":474,"end":479},"obj":"GeneOrGeneProduct"},{"id":"T10","span":{"begin":480,"end":490},"obj":"GeneOrGeneProduct"},{"id":"T11","span":{"begin":521,"end":528},"obj":"GeneOrGeneProduct"},{"id":"T12","span":{"begin":612,"end":618},"obj":"GeneOrGeneProduct"},{"id":"T13","span":{"begin":619,"end":624},"obj":"GeneOrGeneProduct"},{"id":"T14","span":{"begin":636,"end":642},"obj":"GeneOrGeneProduct"},{"id":"T15","span":{"begin":759,"end":763},"obj":"GeneOrGeneProduct"},{"id":"T16","span":{"begin":801,"end":806},"obj":"GeneOrGeneProduct"},{"id":"T17","span":{"begin":1172,"end":1175},"obj":"GeneOrGeneProduct"},{"id":"T18","span":{"begin":1176,"end":1178},"obj":"GeneOrGeneProduct"},{"id":"T19","span":{"begin":1680,"end":1683},"obj":"GeneOrGeneProduct"},{"id":"T20","span":{"begin":1684,"end":1686},"obj":"GeneOrGeneProduct"},{"id":"T21","span":{"begin":1697,"end":1704},"obj":"GeneOrGeneProduct"},{"id":"T22","span":{"begin":1705,"end":1707},"obj":"GeneOrGeneProduct"},{"id":"T23","span":{"begin":1734,"end":1741},"obj":"GeneOrGeneProduct"}],"text":"Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.\nOBJECTIVES: The risk of acute myocardial infarction (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-selective (NS) non-steroidal anti-inflammatory drugs (NSAIDs). We aimed to compare the risks of hospitalization for AMI and GI bleeding among elderly patients using COX-2 inhibitors, NS-NSAIDs and acetaminophen.\nMETHODS: We conducted a retrospective cohort study using administrative data of patients \u003e or =65 years of age who filled a prescription for NSAID or acetaminophen during 1999-2002. Outcomes were compared using Cox regression models with time-dependent exposures.\nRESULTS: Person-years of exposure among non-users of aspirin were: 75,761 to acetaminophen, 42,671 to rofecoxib 65,860 to celecoxib, and 37,495 to NS-NSAIDs. Among users of aspirin, they were: 14,671 to rofecoxib, 22,875 to celecoxib, 9,832 to NS-NSAIDs and 38,048 to acetaminophen. Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51). Among users of aspirin, they were: rofecoxib 1.73 (1.52, 1.98), celecoxib 1.34 (1.19, 1.52), ibuprofen 1.51 (0.95, 2.41), diclofenac 1.69 (1.35, 2.10), naproxen 1.35 (0.97, 1.88) and acetaminophen 1.29 (1.17, 1.42).\nCONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI/GI bleeding. The AMI/GI toxicity of celecoxib was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-NSAIDs. Among users of aspirin, both celecoxib and naproxen seemed to be the least toxic."}

{"project":"LitCoin-GeneOrGeneProduct-v2","denotations":[{"id":"T1","span":{"begin":22,"end":27},"obj":"GeneOrGeneProduct"},{"id":"T2","span":{"begin":28,"end":38},"obj":"GeneOrGeneProduct"},{"id":"T3","span":{"begin":227,"end":232},"obj":"GeneOrGeneProduct"},{"id":"T4","span":{"begin":233,"end":243},"obj":"GeneOrGeneProduct"},{"id":"T5","span":{"begin":474,"end":479},"obj":"GeneOrGeneProduct"},{"id":"T6","span":{"begin":480,"end":490},"obj":"GeneOrGeneProduct"},{"id":"T7","span":{"begin":1734,"end":1741},"obj":"GeneOrGeneProduct"}],"text":"Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.\nOBJECTIVES: The risk of acute myocardial infarction (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-selective (NS) non-steroidal anti-inflammatory drugs (NSAIDs). We aimed to compare the risks of hospitalization for AMI and GI bleeding among elderly patients using COX-2 inhibitors, NS-NSAIDs and acetaminophen.\nMETHODS: We conducted a retrospective cohort study using administrative data of patients \u003e or =65 years of age who filled a prescription for NSAID or acetaminophen during 1999-2002. Outcomes were compared using Cox regression models with time-dependent exposures.\nRESULTS: Person-years of exposure among non-users of aspirin were: 75,761 to acetaminophen, 42,671 to rofecoxib 65,860 to celecoxib, and 37,495 to NS-NSAIDs. Among users of aspirin, they were: 14,671 to rofecoxib, 22,875 to celecoxib, 9,832 to NS-NSAIDs and 38,048 to acetaminophen. Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51). Among users of aspirin, they were: rofecoxib 1.73 (1.52, 1.98), celecoxib 1.34 (1.19, 1.52), ibuprofen 1.51 (0.95, 2.41), diclofenac 1.69 (1.35, 2.10), naproxen 1.35 (0.97, 1.88) and acetaminophen 1.29 (1.17, 1.42).\nCONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI/GI bleeding. The AMI/GI toxicity of celecoxib was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-NSAIDs. Among users of aspirin, both celecoxib and naproxen seemed to be the least toxic."}

{"project":"LitCoin-Disease-MeSH","denotations":[{"id":"T1","span":{"begin":194,"end":215},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":343,"end":355},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":436,"end":444},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":1687,"end":1695},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T5","span":{"begin":1708,"end":1716},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A1","pred":"originalLabel","subj":"T1","obj":"D009203"},{"id":"A2","pred":"originalLabel","subj":"T2","obj":"DISEASE"},{"id":"A3","pred":"originalLabel","subj":"T3","obj":"D006470"},{"id":"A4","pred":"originalLabel","subj":"T4","obj":"D006470"},{"id":"A5","pred":"originalLabel","subj":"T5","obj":"DISEASE"}],"text":"Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.\nOBJECTIVES: The risk of acute myocardial infarction (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-selective (NS) non-steroidal anti-inflammatory drugs (NSAIDs). We aimed to compare the risks of hospitalization for AMI and GI bleeding among elderly patients using COX-2 inhibitors, NS-NSAIDs and acetaminophen.\nMETHODS: We conducted a retrospective cohort study using administrative data of patients \u003e or =65 years of age who filled a prescription for NSAID or acetaminophen during 1999-2002. Outcomes were compared using Cox regression models with time-dependent exposures.\nRESULTS: Person-years of exposure among non-users of aspirin were: 75,761 to acetaminophen, 42,671 to rofecoxib 65,860 to celecoxib, and 37,495 to NS-NSAIDs. Among users of aspirin, they were: 14,671 to rofecoxib, 22,875 to celecoxib, 9,832 to NS-NSAIDs and 38,048 to acetaminophen. Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51). Among users of aspirin, they were: rofecoxib 1.73 (1.52, 1.98), celecoxib 1.34 (1.19, 1.52), ibuprofen 1.51 (0.95, 2.41), diclofenac 1.69 (1.35, 2.10), naproxen 1.35 (0.97, 1.88) and acetaminophen 1.29 (1.17, 1.42).\nCONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI/GI bleeding. The AMI/GI toxicity of celecoxib was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-NSAIDs. Among users of aspirin, both celecoxib and naproxen seemed to be the least toxic."}

{"project":"LitCoin-GeneOrGeneProduct-v3","denotations":[{"id":"T1","span":{"begin":22,"end":27},"obj":"GeneOrGeneProduct"},{"id":"T2","span":{"begin":227,"end":232},"obj":"GeneOrGeneProduct"},{"id":"T3","span":{"begin":474,"end":479},"obj":"GeneOrGeneProduct"}],"text":"Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.\nOBJECTIVES: The risk of acute myocardial infarction (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-selective (NS) non-steroidal anti-inflammatory drugs (NSAIDs). We aimed to compare the risks of hospitalization for AMI and GI bleeding among elderly patients using COX-2 inhibitors, NS-NSAIDs and acetaminophen.\nMETHODS: We conducted a retrospective cohort study using administrative data of patients \u003e or =65 years of age who filled a prescription for NSAID or acetaminophen during 1999-2002. Outcomes were compared using Cox regression models with time-dependent exposures.\nRESULTS: Person-years of exposure among non-users of aspirin were: 75,761 to acetaminophen, 42,671 to rofecoxib 65,860 to celecoxib, and 37,495 to NS-NSAIDs. Among users of aspirin, they were: 14,671 to rofecoxib, 22,875 to celecoxib, 9,832 to NS-NSAIDs and 38,048 to acetaminophen. Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51). Among users of aspirin, they were: rofecoxib 1.73 (1.52, 1.98), celecoxib 1.34 (1.19, 1.52), ibuprofen 1.51 (0.95, 2.41), diclofenac 1.69 (1.35, 2.10), naproxen 1.35 (0.97, 1.88) and acetaminophen 1.29 (1.17, 1.42).\nCONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI/GI bleeding. The AMI/GI toxicity of celecoxib was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-NSAIDs. Among users of aspirin, both celecoxib and naproxen seemed to be the least toxic."}

{"project":"LitCoin_Mondo_095","denotations":[{"id":"T1","span":{"begin":188,"end":215},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":217,"end":220},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":320,"end":322},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":425,"end":428},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T5","span":{"begin":433,"end":444},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T6","span":{"begin":492,"end":494},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T7","span":{"begin":932,"end":934},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T8","span":{"begin":1029,"end":1031},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T9","span":{"begin":1172,"end":1175},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T10","span":{"begin":1680,"end":1683},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T11","span":{"begin":1684,"end":1695},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T12","span":{"begin":1701,"end":1704},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T13","span":{"begin":1819,"end":1821},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A4","pred":"mondo_id","subj":"T4","obj":"0004781"},{"id":"A12","pred":"mondo_id","subj":"T12","obj":"0004781"},{"id":"A9","pred":"mondo_id","subj":"T9","obj":"0004781"},{"id":"A11","pred":"mondo_id","subj":"T11","obj":"0004242"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"0009735"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"0009735"},{"id":"A10","pred":"mondo_id","subj":"T10","obj":"0004781"},{"id":"A8","pred":"mondo_id","subj":"T8","obj":"0009735"},{"id":"A6","pred":"mondo_id","subj":"T6","obj":"0009735"},{"id":"A1","pred":"mondo_id","subj":"T1","obj":"0004781"},{"id":"A13","pred":"mondo_id","subj":"T13","obj":"0009735"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"0004781"},{"id":"A5","pred":"mondo_id","subj":"T5","obj":"0004242"}],"text":"Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.\nOBJECTIVES: The risk of acute myocardial infarction (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-selective (NS) non-steroidal anti-inflammatory drugs (NSAIDs). We aimed to compare the risks of hospitalization for AMI and GI bleeding among elderly patients using COX-2 inhibitors, NS-NSAIDs and acetaminophen.\nMETHODS: We conducted a retrospective cohort study using administrative data of patients \u003e or =65 years of age who filled a prescription for NSAID or acetaminophen during 1999-2002. Outcomes were compared using Cox regression models with time-dependent exposures.\nRESULTS: Person-years of exposure among non-users of aspirin were: 75,761 to acetaminophen, 42,671 to rofecoxib 65,860 to celecoxib, and 37,495 to NS-NSAIDs. Among users of aspirin, they were: 14,671 to rofecoxib, 22,875 to celecoxib, 9,832 to NS-NSAIDs and 38,048 to acetaminophen. Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51). Among users of aspirin, they were: rofecoxib 1.73 (1.52, 1.98), celecoxib 1.34 (1.19, 1.52), ibuprofen 1.51 (0.95, 2.41), diclofenac 1.69 (1.35, 2.10), naproxen 1.35 (0.97, 1.88) and acetaminophen 1.29 (1.17, 1.42).\nCONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI/GI bleeding. The AMI/GI toxicity of celecoxib was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-NSAIDs. Among users of aspirin, both celecoxib and naproxen seemed to be the least toxic."}

{"project":"LitCoin-MeSH-Disease-2","denotations":[{"id":"T1","span":{"begin":194,"end":215},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":217,"end":220},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":343,"end":355},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":425,"end":428},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T5","span":{"begin":436,"end":444},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T6","span":{"begin":1172,"end":1175},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T7","span":{"begin":1680,"end":1683},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T8","span":{"begin":1687,"end":1695},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T9","span":{"begin":1701,"end":1704},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T10","span":{"begin":1705,"end":1716},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A3","pred":"ID:","subj":"T3","obj":"DISEASE"},{"id":"A1","pred":"ID:","subj":"T1","obj":"D009203"},{"id":"A2","pred":"ID:","subj":"T2","obj":"DISEASE"},{"id":"A9","pred":"ID:","subj":"T9","obj":"DISEASE"},{"id":"A6","pred":"ID:","subj":"T6","obj":"DISEASE"},{"id":"A5","pred":"ID:","subj":"T5","obj":"D006470"},{"id":"A7","pred":"ID:","subj":"T7","obj":"DISEASE"},{"id":"A4","pred":"ID:","subj":"T4","obj":"DISEASE"},{"id":"A10","pred":"ID:","subj":"T10","obj":"DISEASE"},{"id":"A8","pred":"ID:","subj":"T8","obj":"D006470"}],"text":"Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.\nOBJECTIVES: The risk of acute myocardial infarction (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-selective (NS) non-steroidal anti-inflammatory drugs (NSAIDs). We aimed to compare the risks of hospitalization for AMI and GI bleeding among elderly patients using COX-2 inhibitors, NS-NSAIDs and acetaminophen.\nMETHODS: We conducted a retrospective cohort study using administrative data of patients \u003e or =65 years of age who filled a prescription for NSAID or acetaminophen during 1999-2002. Outcomes were compared using Cox regression models with time-dependent exposures.\nRESULTS: Person-years of exposure among non-users of aspirin were: 75,761 to acetaminophen, 42,671 to rofecoxib 65,860 to celecoxib, and 37,495 to NS-NSAIDs. Among users of aspirin, they were: 14,671 to rofecoxib, 22,875 to celecoxib, 9,832 to NS-NSAIDs and 38,048 to acetaminophen. Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51). Among users of aspirin, they were: rofecoxib 1.73 (1.52, 1.98), celecoxib 1.34 (1.19, 1.52), ibuprofen 1.51 (0.95, 2.41), diclofenac 1.69 (1.35, 2.10), naproxen 1.35 (0.97, 1.88) and acetaminophen 1.29 (1.17, 1.42).\nCONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI/GI bleeding. The AMI/GI toxicity of celecoxib was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-NSAIDs. Among users of aspirin, both celecoxib and naproxen seemed to be the least toxic."}

{"project":"LitCoin-MONDO_bioort2019","denotations":[{"id":"T1","span":{"begin":194,"end":215},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":217,"end":220},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":425,"end":428},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":436,"end":444},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T5","span":{"begin":1172,"end":1175},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T6","span":{"begin":1680,"end":1683},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T7","span":{"begin":1687,"end":1695},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T8","span":{"begin":1701,"end":1704},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T9","span":{"begin":1705,"end":1716},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A5","pred":"#label","subj":"T5","obj":"DISEASE"},{"id":"A2","pred":"#label","subj":"T2","obj":"DISEASE"},{"id":"A6","pred":"#label","subj":"T6","obj":"DISEASE"},{"id":"A4","pred":"#label","subj":"T4","obj":"D006470"},{"id":"A3","pred":"#label","subj":"T3","obj":"DISEASE"},{"id":"A7","pred":"#label","subj":"T7","obj":"D006470"},{"id":"A9","pred":"#label","subj":"T9","obj":"DISEASE"},{"id":"A8","pred":"#label","subj":"T8","obj":"DISEASE"},{"id":"A1","pred":"#label","subj":"T1","obj":"D009203"}],"text":"Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.\nOBJECTIVES: The risk of acute myocardial infarction (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-selective (NS) non-steroidal anti-inflammatory drugs (NSAIDs). We aimed to compare the risks of hospitalization for AMI and GI bleeding among elderly patients using COX-2 inhibitors, NS-NSAIDs and acetaminophen.\nMETHODS: We conducted a retrospective cohort study using administrative data of patients \u003e or =65 years of age who filled a prescription for NSAID or acetaminophen during 1999-2002. Outcomes were compared using Cox regression models with time-dependent exposures.\nRESULTS: Person-years of exposure among non-users of aspirin were: 75,761 to acetaminophen, 42,671 to rofecoxib 65,860 to celecoxib, and 37,495 to NS-NSAIDs. Among users of aspirin, they were: 14,671 to rofecoxib, 22,875 to celecoxib, 9,832 to NS-NSAIDs and 38,048 to acetaminophen. Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51). Among users of aspirin, they were: rofecoxib 1.73 (1.52, 1.98), celecoxib 1.34 (1.19, 1.52), ibuprofen 1.51 (0.95, 2.41), diclofenac 1.69 (1.35, 2.10), naproxen 1.35 (0.97, 1.88) and acetaminophen 1.29 (1.17, 1.42).\nCONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI/GI bleeding. The AMI/GI toxicity of celecoxib was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-NSAIDs. Among users of aspirin, both celecoxib and naproxen seemed to be the least toxic."}

{"project":"LitCoin-Chemical-MeSH-CHEBI","denotations":[{"id":"T1","span":{"begin":22,"end":38},"obj":"ChemicalEntity"},{"id":"T2","span":{"begin":56,"end":62},"obj":"ChemicalEntity"},{"id":"T3","span":{"begin":217,"end":220},"obj":"ChemicalEntity"},{"id":"T4","span":{"begin":227,"end":243},"obj":"ChemicalEntity"},{"id":"T5","span":{"begin":324,"end":361},"obj":"ChemicalEntity"},{"id":"T6","span":{"begin":363,"end":369},"obj":"ChemicalEntity"},{"id":"T7","span":{"begin":425,"end":428},"obj":"ChemicalEntity"},{"id":"T8","span":{"begin":474,"end":490},"obj":"ChemicalEntity"},{"id":"T9","span":{"begin":495,"end":501},"obj":"ChemicalEntity"},{"id":"T10","span":{"begin":506,"end":519},"obj":"ChemicalEntity"},{"id":"T11","span":{"begin":662,"end":667},"obj":"ChemicalEntity"},{"id":"T12","span":{"begin":671,"end":684},"obj":"ChemicalEntity"},{"id":"T13","span":{"begin":838,"end":845},"obj":"ChemicalEntity"},{"id":"T14","span":{"begin":862,"end":875},"obj":"ChemicalEntity"},{"id":"T15","span":{"begin":887,"end":896},"obj":"ChemicalEntity"},{"id":"T17","span":{"begin":907,"end":916},"obj":"ChemicalEntity"},{"id":"T19","span":{"begin":935,"end":941},"obj":"ChemicalEntity"},{"id":"T20","span":{"begin":958,"end":965},"obj":"ChemicalEntity"},{"id":"T21","span":{"begin":988,"end":997},"obj":"ChemicalEntity"},{"id":"T23","span":{"begin":1009,"end":1018},"obj":"ChemicalEntity"},{"id":"T25","span":{"begin":1032,"end":1038},"obj":"ChemicalEntity"},{"id":"T26","span":{"begin":1053,"end":1066},"obj":"ChemicalEntity"},{"id":"T27","span":{"begin":1087,"end":1094},"obj":"ChemicalEntity"},{"id":"T28","span":{"begin":1172,"end":1175},"obj":"ChemicalEntity"},{"id":"T29","span":{"begin":1186,"end":1199},"obj":"ChemicalEntity"},{"id":"T30","span":{"begin":1209,"end":1216},"obj":"ChemicalEntity"},{"id":"T31","span":{"begin":1230,"end":1239},"obj":"ChemicalEntity"},{"id":"T33","span":{"begin":1259,"end":1268},"obj":"ChemicalEntity"},{"id":"T35","span":{"begin":1288,"end":1296},"obj":"ChemicalEntity"},{"id":"T38","span":{"begin":1316,"end":1326},"obj":"ChemicalEntity"},{"id":"T40","span":{"begin":1349,"end":1358},"obj":"ChemicalEntity"},{"id":"T43","span":{"begin":1393,"end":1400},"obj":"ChemicalEntity"},{"id":"T44","span":{"begin":1413,"end":1422},"obj":"ChemicalEntity"},{"id":"T46","span":{"begin":1442,"end":1451},"obj":"ChemicalEntity"},{"id":"T48","span":{"begin":1471,"end":1480},"obj":"ChemicalEntity"},{"id":"T51","span":{"begin":1500,"end":1510},"obj":"ChemicalEntity"},{"id":"T53","span":{"begin":1530,"end":1538},"obj":"ChemicalEntity"},{"id":"T56","span":{"begin":1561,"end":1574},"obj":"ChemicalEntity"},{"id":"T57","span":{"begin":1625,"end":1632},"obj":"ChemicalEntity"},{"id":"T58","span":{"begin":1634,"end":1642},"obj":"ChemicalEntity"},{"id":"T61","span":{"begin":1680,"end":1683},"obj":"ChemicalEntity"},{"id":"T62","span":{"begin":1701,"end":1704},"obj":"ChemicalEntity"},{"id":"T63","span":{"begin":1720,"end":1729},"obj":"ChemicalEntity"},{"id":"T65","span":{"begin":1753,"end":1766},"obj":"ChemicalEntity"},{"id":"T66","span":{"begin":1805,"end":1814},"obj":"ChemicalEntity"},{"id":"T68","span":{"begin":1822,"end":1828},"obj":"ChemicalEntity"},{"id":"T69","span":{"begin":1845,"end":1852},"obj":"ChemicalEntity"},{"id":"T70","span":{"begin":1859,"end":1868},"obj":"ChemicalEntity"},{"id":"T72","span":{"begin":1873,"end":1881},"obj":"ChemicalEntity"}],"attributes":[{"id":"A30","pred":"ID:","subj":"T30","obj":"D001241"},{"id":"A69","pred":"ID:","subj":"T69","obj":"D001241"},{"id":"A9","pred":"ID:","subj":"T9","obj":"ChemicalEntity"},{"id":"A57","pred":"ID:","subj":"T57","obj":"D001241"},{"id":"A2","pred":"ID:","subj":"T2","obj":"ChemicalEntity"},{"id":"A20","pred":"ID:","subj":"T20","obj":"D001241"},{"id":"A29","pred":"ID:","subj":"T29","obj":"D000082"},{"id":"A38","pred":"ID:","subj":"T38","obj":"D004008"},{"id":"A39","pred":"ID:","subj":"T38","obj":"http://purl.obolibrary.org/obo/CHEBI_47381"},{"id":"A12","pred":"ID:","subj":"T12","obj":"D000082"},{"id":"A31","pred":"ID:","subj":"T31","obj":"C116926"},{"id":"A32","pred":"ID:","subj":"T31","obj":"http://purl.obolibrary.org/obo/CHEBI_8887"},{"id":"A51","pred":"ID:","subj":"T51","obj":"D004008"},{"id":"A52","pred":"ID:","subj":"T51","obj":"http://purl.obolibrary.org/obo/CHEBI_47381"},{"id":"A63","pred":"ID:","subj":"T63","obj":"D000068579"},{"id":"A64","pred":"ID:","subj":"T63","obj":"http://purl.obolibrary.org/obo/CHEBI_41423"},{"id":"A56","pred":"ID:","subj":"T56","obj":"D000082"},{"id":"A68","pred":"ID:","subj":"T68","obj":"ChemicalEntity"},{"id":"A48","pred":"ID:","subj":"T48","obj":"D007052"},{"id":"A49","pred":"ID:","subj":"T48","obj":"http://purl.obolibrary.org/obo/CHEBI_5855"},{"id":"A50","pred":"ID:","subj":"T48","obj":"http://purl.obolibrary.org/obo/CHEBI_132922"},{"id":"A35","pred":"ID:","subj":"T35","obj":"D009288"},{"id":"A36","pred":"ID:","subj":"T35","obj":"http://purl.obolibrary.org/obo/CHEBI_7476"},{"id":"A37","pred":"ID:","subj":"T35","obj":"http://purl.obolibrary.org/obo/CHEBI_59527"},{"id":"A58","pred":"ID:","subj":"T58","obj":"D009288"},{"id":"A59","pred":"ID:","subj":"T58","obj":"http://purl.obolibrary.org/obo/CHEBI_7476"},{"id":"A60","pred":"ID:","subj":"T58","obj":"http://purl.obolibrary.org/obo/CHEBI_59527"},{"id":"A13","pred":"ID:","subj":"T13","obj":"D001241"},{"id":"A46","pred":"ID:","subj":"T46","obj":"D000068579"},{"id":"A47","pred":"ID:","subj":"T46","obj":"http://purl.obolibrary.org/obo/CHEBI_41423"},{"id":"A10","pred":"ID:","subj":"T10","obj":"D000082"},{"id":"A11","pred":"ID:","subj":"T11","obj":"ChemicalEntity"},{"id":"A23","pred":"ID:","subj":"T23","obj":"D000068579"},{"id":"A24","pred":"ID:","subj":"T23","obj":"http://purl.obolibrary.org/obo/CHEBI_41423"},{"id":"A26","pred":"ID:","subj":"T26","obj":"D000082"},{"id":"A28","pred":"ID:","subj":"T28","obj":"http://purl.obolibrary.org/obo/CHEBI_65009"},{"id":"A61","pred":"ID:","subj":"T61","obj":"http://purl.obolibrary.org/obo/CHEBI_65009"},{"id":"A65","pred":"ID:","subj":"T65","obj":"D000082"},{"id":"A44","pred":"ID:","subj":"T44","obj":"C116926"},{"id":"A45","pred":"ID:","subj":"T44","obj":"http://purl.obolibrary.org/obo/CHEBI_8887"},{"id":"A14","pred":"ID:","subj":"T14","obj":"D000082"},{"id":"A15","pred":"ID:","subj":"T15","obj":"C116926"},{"id":"A16","pred":"ID:","subj":"T15","obj":"http://purl.obolibrary.org/obo/CHEBI_8887"},{"id":"A4","pred":"ID:","subj":"T4","obj":"ChemicalEntity"},{"id":"A1","pred":"ID:","subj":"T1","obj":"ChemicalEntity"},{"id":"A5","pred":"ID:","subj":"T5","obj":"ChemicalEntity"},{"id":"A70","pred":"ID:","subj":"T70","obj":"D000068579"},{"id":"A71","pred":"ID:","subj":"T70","obj":"http://purl.obolibrary.org/obo/CHEBI_41423"},{"id":"A6","pred":"ID:","subj":"T6","obj":"ChemicalEntity"},{"id":"A17","pred":"ID:","subj":"T17","obj":"D000068579"},{"id":"A18","pred":"ID:","subj":"T17","obj":"http://purl.obolibrary.org/obo/CHEBI_41423"},{"id":"A66","pred":"ID:","subj":"T66","obj":"C116926"},{"id":"A67","pred":"ID:","subj":"T66","obj":"http://purl.obolibrary.org/obo/CHEBI_8887"},{"id":"A40","pred":"ID:","subj":"T40","obj":"D007052"},{"id":"A41","pred":"ID:","subj":"T40","obj":"http://purl.obolibrary.org/obo/CHEBI_5855"},{"id":"A42","pred":"ID:","subj":"T40","obj":"http://purl.obolibrary.org/obo/CHEBI_132922"},{"id":"A72","pred":"ID:","subj":"T72","obj":"D009288"},{"id":"A73","pred":"ID:","subj":"T72","obj":"http://purl.obolibrary.org/obo/CHEBI_7476"},{"id":"A74","pred":"ID:","subj":"T72","obj":"http://purl.obolibrary.org/obo/CHEBI_59527"},{"id":"A25","pred":"ID:","subj":"T25","obj":"ChemicalEntity"},{"id":"A3","pred":"ID:","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_65009"},{"id":"A19","pred":"ID:","subj":"T19","obj":"ChemicalEntity"},{"id":"A7","pred":"ID:","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_65009"},{"id":"A27","pred":"ID:","subj":"T27","obj":"D001241"},{"id":"A43","pred":"ID:","subj":"T43","obj":"D001241"},{"id":"A53","pred":"ID:","subj":"T53","obj":"D009288"},{"id":"A54","pred":"ID:","subj":"T53","obj":"http://purl.obolibrary.org/obo/CHEBI_7476"},{"id":"A55","pred":"ID:","subj":"T53","obj":"http://purl.obolibrary.org/obo/CHEBI_59527"},{"id":"A33","pred":"ID:","subj":"T33","obj":"D000068579"},{"id":"A34","pred":"ID:","subj":"T33","obj":"http://purl.obolibrary.org/obo/CHEBI_41423"},{"id":"A8","pred":"ID:","subj":"T8","obj":"ChemicalEntity"},{"id":"A21","pred":"ID:","subj":"T21","obj":"C116926"},{"id":"A22","pred":"ID:","subj":"T21","obj":"http://purl.obolibrary.org/obo/CHEBI_8887"},{"id":"A62","pred":"ID:","subj":"T62","obj":"http://purl.obolibrary.org/obo/CHEBI_65009"}],"text":"Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.\nOBJECTIVES: The risk of acute myocardial infarction (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-selective (NS) non-steroidal anti-inflammatory drugs (NSAIDs). We aimed to compare the risks of hospitalization for AMI and GI bleeding among elderly patients using COX-2 inhibitors, NS-NSAIDs and acetaminophen.\nMETHODS: We conducted a retrospective cohort study using administrative data of patients \u003e or =65 years of age who filled a prescription for NSAID or acetaminophen during 1999-2002. Outcomes were compared using Cox regression models with time-dependent exposures.\nRESULTS: Person-years of exposure among non-users of aspirin were: 75,761 to acetaminophen, 42,671 to rofecoxib 65,860 to celecoxib, and 37,495 to NS-NSAIDs. Among users of aspirin, they were: 14,671 to rofecoxib, 22,875 to celecoxib, 9,832 to NS-NSAIDs and 38,048 to acetaminophen. Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51). Among users of aspirin, they were: rofecoxib 1.73 (1.52, 1.98), celecoxib 1.34 (1.19, 1.52), ibuprofen 1.51 (0.95, 2.41), diclofenac 1.69 (1.35, 2.10), naproxen 1.35 (0.97, 1.88) and acetaminophen 1.29 (1.17, 1.42).\nCONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI/GI bleeding. The AMI/GI toxicity of celecoxib was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-NSAIDs. Among users of aspirin, both celecoxib and naproxen seemed to be the least toxic."}

{"project":"LitCoin-NCBITaxon-2","denotations":[{"id":"T1","span":{"begin":217,"end":220},"obj":"OrganismTaxon"},{"id":"T2","span":{"begin":425,"end":428},"obj":"OrganismTaxon"},{"id":"T3","span":{"begin":459,"end":467},"obj":"OrganismTaxon"},{"id":"T4","span":{"begin":601,"end":609},"obj":"OrganismTaxon"},{"id":"T5","span":{"begin":1172,"end":1175},"obj":"OrganismTaxon"},{"id":"T6","span":{"begin":1680,"end":1683},"obj":"OrganismTaxon"},{"id":"T7","span":{"begin":1701,"end":1704},"obj":"OrganismTaxon"}],"text":"Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.\nOBJECTIVES: The risk of acute myocardial infarction (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-selective (NS) non-steroidal anti-inflammatory drugs (NSAIDs). We aimed to compare the risks of hospitalization for AMI and GI bleeding among elderly patients using COX-2 inhibitors, NS-NSAIDs and acetaminophen.\nMETHODS: We conducted a retrospective cohort study using administrative data of patients \u003e or =65 years of age who filled a prescription for NSAID or acetaminophen during 1999-2002. Outcomes were compared using Cox regression models with time-dependent exposures.\nRESULTS: Person-years of exposure among non-users of aspirin were: 75,761 to acetaminophen, 42,671 to rofecoxib 65,860 to celecoxib, and 37,495 to NS-NSAIDs. Among users of aspirin, they were: 14,671 to rofecoxib, 22,875 to celecoxib, 9,832 to NS-NSAIDs and 38,048 to acetaminophen. Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51). Among users of aspirin, they were: rofecoxib 1.73 (1.52, 1.98), celecoxib 1.34 (1.19, 1.52), ibuprofen 1.51 (0.95, 2.41), diclofenac 1.69 (1.35, 2.10), naproxen 1.35 (0.97, 1.88) and acetaminophen 1.29 (1.17, 1.42).\nCONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI/GI bleeding. The AMI/GI toxicity of celecoxib was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-NSAIDs. Among users of aspirin, both celecoxib and naproxen seemed to be the least toxic."}

{"project":"LitCoin-training-merged","denotations":[{"id":"T72","span":{"begin":1873,"end":1881},"obj":"ChemicalEntity"},{"id":"T70","span":{"begin":1859,"end":1868},"obj":"ChemicalEntity"},{"id":"T69","span":{"begin":1845,"end":1852},"obj":"ChemicalEntity"},{"id":"T68","span":{"begin":1822,"end":1828},"obj":"ChemicalEntity"},{"id":"T66","span":{"begin":1805,"end":1814},"obj":"ChemicalEntity"},{"id":"T65","span":{"begin":1753,"end":1766},"obj":"ChemicalEntity"},{"id":"T63","span":{"begin":1720,"end":1729},"obj":"ChemicalEntity"},{"id":"T62","span":{"begin":1701,"end":1704},"obj":"ChemicalEntity"},{"id":"T61","span":{"begin":1680,"end":1683},"obj":"ChemicalEntity"},{"id":"T58","span":{"begin":1634,"end":1642},"obj":"ChemicalEntity"},{"id":"T57","span":{"begin":1625,"end":1632},"obj":"ChemicalEntity"},{"id":"T56","span":{"begin":1561,"end":1574},"obj":"ChemicalEntity"},{"id":"T53","span":{"begin":1530,"end":1538},"obj":"ChemicalEntity"},{"id":"T51","span":{"begin":1500,"end":1510},"obj":"ChemicalEntity"},{"id":"T48","span":{"begin":1471,"end":1480},"obj":"ChemicalEntity"},{"id":"T46","span":{"begin":1442,"end":1451},"obj":"ChemicalEntity"},{"id":"T44","span":{"begin":1413,"end":1422},"obj":"ChemicalEntity"},{"id":"T43","span":{"begin":1393,"end":1400},"obj":"ChemicalEntity"},{"id":"T40","span":{"begin":1349,"end":1358},"obj":"ChemicalEntity"},{"id":"T38","span":{"begin":1316,"end":1326},"obj":"ChemicalEntity"},{"id":"T35","span":{"begin":1288,"end":1296},"obj":"ChemicalEntity"},{"id":"T33","span":{"begin":1259,"end":1268},"obj":"ChemicalEntity"},{"id":"T31","span":{"begin":1230,"end":1239},"obj":"ChemicalEntity"},{"id":"T30","span":{"begin":1209,"end":1216},"obj":"ChemicalEntity"},{"id":"T29","span":{"begin":1186,"end":1199},"obj":"ChemicalEntity"},{"id":"T28","span":{"begin":1172,"end":1175},"obj":"ChemicalEntity"},{"id":"T27","span":{"begin":1087,"end":1094},"obj":"ChemicalEntity"},{"id":"T26","span":{"begin":1053,"end":1066},"obj":"ChemicalEntity"},{"id":"T25","span":{"begin":1032,"end":1038},"obj":"ChemicalEntity"},{"id":"T23","span":{"begin":1009,"end":1018},"obj":"ChemicalEntity"},{"id":"T21","span":{"begin":988,"end":997},"obj":"ChemicalEntity"},{"id":"T20","span":{"begin":958,"end":965},"obj":"ChemicalEntity"},{"id":"T19","span":{"begin":935,"end":941},"obj":"ChemicalEntity"},{"id":"T17","span":{"begin":907,"end":916},"obj":"ChemicalEntity"},{"id":"T15","span":{"begin":887,"end":896},"obj":"ChemicalEntity"},{"id":"T14","span":{"begin":862,"end":875},"obj":"ChemicalEntity"},{"id":"T13","span":{"begin":838,"end":845},"obj":"ChemicalEntity"},{"id":"T12","span":{"begin":671,"end":684},"obj":"ChemicalEntity"},{"id":"T11","span":{"begin":662,"end":667},"obj":"ChemicalEntity"},{"id":"T10","span":{"begin":506,"end":519},"obj":"ChemicalEntity"},{"id":"T9","span":{"begin":495,"end":501},"obj":"ChemicalEntity"},{"id":"T8","span":{"begin":474,"end":490},"obj":"ChemicalEntity"},{"id":"T7","span":{"begin":425,"end":428},"obj":"ChemicalEntity"},{"id":"T6","span":{"begin":363,"end":369},"obj":"ChemicalEntity"},{"id":"T5","span":{"begin":324,"end":361},"obj":"ChemicalEntity"},{"id":"T4","span":{"begin":227,"end":243},"obj":"ChemicalEntity"},{"id":"T3","span":{"begin":217,"end":220},"obj":"ChemicalEntity"},{"id":"T2","span":{"begin":56,"end":62},"obj":"ChemicalEntity"},{"id":"T1","span":{"begin":22,"end":38},"obj":"ChemicalEntity"},{"id":"T37081","span":{"begin":474,"end":479},"obj":"GeneOrGeneProduct"},{"id":"T16034","span":{"begin":227,"end":232},"obj":"GeneOrGeneProduct"},{"id":"T13836","span":{"begin":22,"end":27},"obj":"GeneOrGeneProduct"},{"id":"T64220","span":{"begin":1705,"end":1716},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T11476","span":{"begin":1701,"end":1704},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T42308","span":{"begin":1687,"end":1695},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T63280","span":{"begin":1680,"end":1683},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T47343","span":{"begin":1172,"end":1175},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T18308","span":{"begin":436,"end":444},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T36899","span":{"begin":425,"end":428},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T47431","span":{"begin":217,"end":220},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3005","span":{"begin":194,"end":215},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T6691","span":{"begin":1701,"end":1704},"obj":"OrganismTaxon"},{"id":"T2100","span":{"begin":1680,"end":1683},"obj":"OrganismTaxon"},{"id":"T71975","span":{"begin":1172,"end":1175},"obj":"OrganismTaxon"},{"id":"T94435","span":{"begin":601,"end":609},"obj":"OrganismTaxon"},{"id":"T71946","span":{"begin":459,"end":467},"obj":"OrganismTaxon"},{"id":"T81943","span":{"begin":425,"end":428},"obj":"OrganismTaxon"},{"id":"T76475","span":{"begin":217,"end":220},"obj":"OrganismTaxon"}],"attributes":[{"id":"A40663","pred":"#label","subj":"T64220","obj":"DISEASE"},{"id":"A19","pred":"ID:","subj":"T19","obj":"ChemicalEntity"},{"id":"A42","pred":"ID:","subj":"T40","obj":"http://purl.obolibrary.org/obo/CHEBI_132922"},{"id":"A41","pred":"ID:","subj":"T40","obj":"http://purl.obolibrary.org/obo/CHEBI_5855"},{"id":"A40","pred":"ID:","subj":"T40","obj":"D007052"},{"id":"A5","pred":"ID:","subj":"T5","obj":"ChemicalEntity"},{"id":"A32","pred":"ID:","subj":"T31","obj":"http://purl.obolibrary.org/obo/CHEBI_8887"},{"id":"A31","pred":"ID:","subj":"T31","obj":"C116926"},{"id":"A17535","pred":"#label","subj":"T63280","obj":"DISEASE"},{"id":"A56","pred":"ID:","subj":"T56","obj":"D000082"},{"id":"A83692","pred":"#label","subj":"T3005","obj":"D009203"},{"id":"A25","pred":"ID:","subj":"T25","obj":"ChemicalEntity"},{"id":"A24","pred":"ID:","subj":"T23","obj":"http://purl.obolibrary.org/obo/CHEBI_41423"},{"id":"A23","pred":"ID:","subj":"T23","obj":"D000068579"},{"id":"A14","pred":"ID:","subj":"T14","obj":"D000082"},{"id":"A8","pred":"ID:","subj":"T8","obj":"ChemicalEntity"},{"id":"A10","pred":"ID:","subj":"T10","obj":"D000082"},{"id":"A68","pred":"ID:","subj":"T68","obj":"ChemicalEntity"},{"id":"A3","pred":"ID:","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_65009"},{"id":"A2","pred":"ID:","subj":"T2","obj":"ChemicalEntity"},{"id":"A26","pred":"ID:","subj":"T26","obj":"D000082"},{"id":"A16","pred":"ID:","subj":"T15","obj":"http://purl.obolibrary.org/obo/CHEBI_8887"},{"id":"A15","pred":"ID:","subj":"T15","obj":"C116926"},{"id":"A93415","pred":"#label","subj":"T18308","obj":"D006470"},{"id":"A22","pred":"ID:","subj":"T21","obj":"http://purl.obolibrary.org/obo/CHEBI_8887"},{"id":"A21","pred":"ID:","subj":"T21","obj":"C116926"},{"id":"A13","pred":"ID:","subj":"T13","obj":"D001241"},{"id":"A55","pred":"ID:","subj":"T53","obj":"http://purl.obolibrary.org/obo/CHEBI_59527"},{"id":"A54","pred":"ID:","subj":"T53","obj":"http://purl.obolibrary.org/obo/CHEBI_7476"},{"id":"A53","pred":"ID:","subj":"T53","obj":"D009288"},{"id":"A67","pred":"ID:","subj":"T66","obj":"http://purl.obolibrary.org/obo/CHEBI_8887"},{"id":"A66","pred":"ID:","subj":"T66","obj":"C116926"},{"id":"A1","pred":"ID:","subj":"T1","obj":"ChemicalEntity"},{"id":"A30","pred":"ID:","subj":"T30","obj":"D001241"},{"id":"A20","pred":"ID:","subj":"T20","obj":"D001241"},{"id":"A86823","pred":"#label","subj":"T36899","obj":"DISEASE"},{"id":"A49325","pred":"#label","subj":"T11476","obj":"DISEASE"},{"id":"A37","pred":"ID:","subj":"T35","obj":"http://purl.obolibrary.org/obo/CHEBI_59527"},{"id":"A36","pred":"ID:","subj":"T35","obj":"http://purl.obolibrary.org/obo/CHEBI_7476"},{"id":"A35","pred":"ID:","subj":"T35","obj":"D009288"},{"id":"A52","pred":"ID:","subj":"T51","obj":"http://purl.obolibrary.org/obo/CHEBI_47381"},{"id":"A51","pred":"ID:","subj":"T51","obj":"D004008"},{"id":"A18","pred":"ID:","subj":"T17","obj":"http://purl.obolibrary.org/obo/CHEBI_41423"},{"id":"A17","pred":"ID:","subj":"T17","obj":"D000068579"},{"id":"A39","pred":"ID:","subj":"T38","obj":"http://purl.obolibrary.org/obo/CHEBI_47381"},{"id":"A38","pred":"ID:","subj":"T38","obj":"D004008"},{"id":"A65","pred":"ID:","subj":"T65","obj":"D000082"},{"id":"A4721","pred":"#label","subj":"T47431","obj":"DISEASE"},{"id":"A74","pred":"ID:","subj":"T72","obj":"http://purl.obolibrary.org/obo/CHEBI_59527"},{"id":"A73","pred":"ID:","subj":"T72","obj":"http://purl.obolibrary.org/obo/CHEBI_7476"},{"id":"A72","pred":"ID:","subj":"T72","obj":"D009288"},{"id":"A64","pred":"ID:","subj":"T63","obj":"http://purl.obolibrary.org/obo/CHEBI_41423"},{"id":"A63","pred":"ID:","subj":"T63","obj":"D000068579"},{"id":"A12","pred":"ID:","subj":"T12","obj":"D000082"},{"id":"A34","pred":"ID:","subj":"T33","obj":"http://purl.obolibrary.org/obo/CHEBI_41423"},{"id":"A33","pred":"ID:","subj":"T33","obj":"D000068579"},{"id":"A28","pred":"ID:","subj":"T28","obj":"http://purl.obolibrary.org/obo/CHEBI_65009"},{"id":"A69","pred":"ID:","subj":"T69","obj":"D001241"},{"id":"A40604","pred":"#label","subj":"T47343","obj":"DISEASE"},{"id":"A7","pred":"ID:","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_65009"},{"id":"A6439","pred":"#label","subj":"T42308","obj":"D006470"},{"id":"A4","pred":"ID:","subj":"T4","obj":"ChemicalEntity"},{"id":"A45","pred":"ID:","subj":"T44","obj":"http://purl.obolibrary.org/obo/CHEBI_8887"},{"id":"A44","pred":"ID:","subj":"T44","obj":"C116926"},{"id":"A6","pred":"ID:","subj":"T6","obj":"ChemicalEntity"},{"id":"A50","pred":"ID:","subj":"T48","obj":"http://purl.obolibrary.org/obo/CHEBI_132922"},{"id":"A49","pred":"ID:","subj":"T48","obj":"http://purl.obolibrary.org/obo/CHEBI_5855"},{"id":"A48","pred":"ID:","subj":"T48","obj":"D007052"},{"id":"A60","pred":"ID:","subj":"T58","obj":"http://purl.obolibrary.org/obo/CHEBI_59527"},{"id":"A59","pred":"ID:","subj":"T58","obj":"http://purl.obolibrary.org/obo/CHEBI_7476"},{"id":"A58","pred":"ID:","subj":"T58","obj":"D009288"},{"id":"A71","pred":"ID:","subj":"T70","obj":"http://purl.obolibrary.org/obo/CHEBI_41423"},{"id":"A70","pred":"ID:","subj":"T70","obj":"D000068579"},{"id":"A62","pred":"ID:","subj":"T62","obj":"http://purl.obolibrary.org/obo/CHEBI_65009"},{"id":"A61","pred":"ID:","subj":"T61","obj":"http://purl.obolibrary.org/obo/CHEBI_65009"},{"id":"A47","pred":"ID:","subj":"T46","obj":"http://purl.obolibrary.org/obo/CHEBI_41423"},{"id":"A46","pred":"ID:","subj":"T46","obj":"D000068579"},{"id":"A29","pred":"ID:","subj":"T29","obj":"D000082"},{"id":"A27","pred":"ID:","subj":"T27","obj":"D001241"},{"id":"A9","pred":"ID:","subj":"T9","obj":"ChemicalEntity"},{"id":"A57","pred":"ID:","subj":"T57","obj":"D001241"},{"id":"A43","pred":"ID:","subj":"T43","obj":"D001241"},{"id":"A11","pred":"ID:","subj":"T11","obj":"ChemicalEntity"}],"text":"Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.\nOBJECTIVES: The risk of acute myocardial infarction (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-selective (NS) non-steroidal anti-inflammatory drugs (NSAIDs). We aimed to compare the risks of hospitalization for AMI and GI bleeding among elderly patients using COX-2 inhibitors, NS-NSAIDs and acetaminophen.\nMETHODS: We conducted a retrospective cohort study using administrative data of patients \u003e or =65 years of age who filled a prescription for NSAID or acetaminophen during 1999-2002. Outcomes were compared using Cox regression models with time-dependent exposures.\nRESULTS: Person-years of exposure among non-users of aspirin were: 75,761 to acetaminophen, 42,671 to rofecoxib 65,860 to celecoxib, and 37,495 to NS-NSAIDs. Among users of aspirin, they were: 14,671 to rofecoxib, 22,875 to celecoxib, 9,832 to NS-NSAIDs and 38,048 to acetaminophen. Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51). Among users of aspirin, they were: rofecoxib 1.73 (1.52, 1.98), celecoxib 1.34 (1.19, 1.52), ibuprofen 1.51 (0.95, 2.41), diclofenac 1.69 (1.35, 2.10), naproxen 1.35 (0.97, 1.88) and acetaminophen 1.29 (1.17, 1.42).\nCONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI/GI bleeding. The AMI/GI toxicity of celecoxib was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-NSAIDs. Among users of aspirin, both celecoxib and naproxen seemed to be the least toxic."}

{"project":"PubmedHPO","denotations":[{"id":"T1","span":{"begin":194,"end":215},"obj":"HP_0001658"}],"text":"Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.\nOBJECTIVES: The risk of acute myocardial infarction (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-selective (NS) non-steroidal anti-inflammatory drugs (NSAIDs). We aimed to compare the risks of hospitalization for AMI and GI bleeding among elderly patients using COX-2 inhibitors, NS-NSAIDs and acetaminophen.\nMETHODS: We conducted a retrospective cohort study using administrative data of patients \u003e or =65 years of age who filled a prescription for NSAID or acetaminophen during 1999-2002. Outcomes were compared using Cox regression models with time-dependent exposures.\nRESULTS: Person-years of exposure among non-users of aspirin were: 75,761 to acetaminophen, 42,671 to rofecoxib 65,860 to celecoxib, and 37,495 to NS-NSAIDs. Among users of aspirin, they were: 14,671 to rofecoxib, 22,875 to celecoxib, 9,832 to NS-NSAIDs and 38,048 to acetaminophen. Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51). Among users of aspirin, they were: rofecoxib 1.73 (1.52, 1.98), celecoxib 1.34 (1.19, 1.52), ibuprofen 1.51 (0.95, 2.41), diclofenac 1.69 (1.35, 2.10), naproxen 1.35 (0.97, 1.88) and acetaminophen 1.29 (1.17, 1.42).\nCONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI/GI bleeding. The AMI/GI toxicity of celecoxib was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-NSAIDs. Among users of aspirin, both celecoxib and naproxen seemed to be the least toxic."}